Data from Phase III trial of toripalimab in combination with chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma presented at conference

An interim analysis of the JUPITER-02 study met its primary endpoint, with the addition of toripalimab to chemotherapy associated with improved progression-free survival compared to chemotherapy alone (median 11.7 v 8.0 months; HR 0.52; 95% CI 0.36-0.74; p=0.0003).

Biospace Inc.